Last updated: August 1, 2026
Betrixaban, marketed as Bevyxxa by Portola Pharmaceuticals, is an oral direct factor Xa inhibitor approved by the U.S. Food and Drug Administration in 2017 for extended venous thromboembolism prevention in acutely ill medical patients. Its commercial use ended after limited uptake, and no active development program or meaningful commercial market remains. The drug has no established biosimilar pathway because it is a small molecule, but generic competition and product discontinuation eliminated its commercial value.
What is the current FDA status of betrixaban?
Betrixaban is FDA-approved but commercially discontinued in the United States.
The FDA approved Bevyxxa on June 23, 2017, for the prevention of venous thromboembolism in adults hospitalized for an acute illness who have risk factors for thromboembolic complications and are at high risk for complications from bleeding [1].
The approved regimen was:
| Parameter |
FDA-approved information |
| Active ingredient |
Betrixaban |
| Brand |
Bevyxxa |
| Drug class |
Oral direct factor Xa inhibitor |
| Approval date |
June 23, 2017 |
| Indication |
Extended VTE prophylaxis in acutely ill medical patients |
| Standard dose |
160 mg on Day 1, followed by 80 mg once daily |
| Renal impairment dose |
80 mg on Day 1, followed by 40 mg once daily |
| Treatment duration |
35 to 42 days |
| Administration |
With food |
| Original sponsor |
Portola Pharmaceuticals |
| Current commercial status |
Discontinued |
Portola was acquired by Alexion Pharmaceuticals in 2020. Alexion later became part of AstraZeneca. Bevyxxa was not retained as a significant commercial product, and the U.S. market no longer has an active branded betrixaban franchise.
What clinical trials supported betrixaban approval?
The principal efficacy evidence came from the APEX trial, a randomized Phase 3 study comparing extended-duration betrixaban with standard-duration enoxaparin in acutely ill medical patients.
How did the APEX trial perform?
The APEX study enrolled approximately 7,500 patients and evaluated betrixaban for 35 to 42 days against enoxaparin administered for approximately 6 to 14 days [2].
The trial used a hierarchical statistical design. Betrixaban did not achieve the primary endpoint in the full intention-to-treat population at the prespecified significance threshold. It did demonstrate a favorable result in the prespecified subgroup of patients with elevated D-dimer levels, and the FDA approved the drug for the narrower high-risk population reflected in the label.
| APEX element |
Result |
| Study type |
Randomized, double-blind, Phase 3 |
| Population |
Acutely ill medical inpatients |
| Experimental treatment |
Extended-duration betrixaban |
| Comparator |
Standard-duration enoxaparin |
| Treatment period |
35 to 42 days for betrixaban |
| Primary clinical focus |
VTE prevention |
| Main efficacy issue |
Overall primary endpoint not statistically significant under the hierarchical design |
| Regulatory outcome |
FDA approval for selected high-risk patients |
The APEX trial reported lower rates of venous thromboembolism in selected patients but also showed a higher rate of clinically relevant bleeding. The risk-benefit profile was acceptable for the restricted population, but it did not establish betrixaban as a broad replacement for inpatient anticoagulants or existing oral factor Xa inhibitors.
What other clinical trials evaluated betrixaban?
Betrixaban development centered on extended VTE prophylaxis. The APEX program was the pivotal clinical effort. Earlier studies evaluated pharmacokinetics, pharmacodynamics, dose selection, and safety in healthy volunteers and patient populations.
No major late-stage program established a second approved indication comparable to atrial fibrillation stroke prevention, treatment of acute VTE, or secondary prevention after myocardial infarction.
Did betrixaban receive approval for atrial fibrillation or VTE treatment?
No. Betrixaban was not approved for:
- Stroke prevention in nonvalvular atrial fibrillation
- Initial treatment of deep-vein thrombosis
- Initial treatment of pulmonary embolism
- Long-term prevention of recurrent VTE
- Acute coronary syndrome
- Mechanical heart-valve anticoagulation
- Pediatric anticoagulation
Those limitations materially reduced its market size. Rivaroxaban, apixaban, edoxaban and dabigatran had broader indications and stronger physician familiarity.
Why did betrixaban fail commercially?
Betrixaban entered a market dominated by established anticoagulants with broader labels, larger commercial infrastructures and more familiar dosing profiles.
The main commercial constraints were:
- Narrow indication. The FDA label targeted acutely ill medical patients at high VTE risk, rather than the much larger atrial fibrillation and VTE-treatment populations.
- Extended prophylaxis complexity. Physicians had to identify patients appropriate for 35 to 42 days of therapy after hospitalization.
- Bleeding concerns. Extended anticoagulation in medically ill patients requires careful risk selection.
- Competition from established drugs. Eliquis, Xarelto, Savaysa and Pradaxa had broader clinical positioning.
- Hospital formulary resistance. Medical centers generally had entrenched protocols for low-molecular-weight heparin and established oral anticoagulants.
- Limited post-approval momentum. Betrixaban did not generate a second major indication to support a larger sales platform.
The product also entered the market without the scale of the commercial organizations supporting Bristol Myers Squibb/Pfizer, Johnson & Johnson, Bayer, Daiichi Sankyo and Boehringer Ingelheim.
How did betrixaban compare with competing anticoagulants?
| Drug |
Main approved use |
Dosing advantage |
Commercial position |
| Betrixaban |
Extended VTE prophylaxis in selected acutely ill adults |
Once daily |
Discontinued and commercially inactive |
| Apixaban |
Atrial fibrillation, VTE treatment and prevention |
Twice daily; broad label |
Major global anticoagulant |
| Rivaroxaban |
Atrial fibrillation, VTE, coronary and peripheral artery disease |
Once daily for several indications |
Major global anticoagulant |
| Edoxaban |
Atrial fibrillation and VTE |
Once daily |
Established but smaller than apixaban and rivaroxaban |
| Dabigatran |
Atrial fibrillation and VTE |
Twice daily |
Established direct thrombin inhibitor |
| Enoxaparin |
Inpatient VTE prophylaxis and treatment |
Injectable |
Standard hospital comparator |
Betrixaban's once-daily schedule was commercially attractive, but that advantage was insufficient to offset its narrow approved use and limited clinical adoption.
Was betrixaban safer than other direct oral anticoagulants?
The clinical record does not support a broad safety superiority claim. Betrixaban's extended-duration regimen produced clinically relevant bleeding, although fatal bleeding and intracranial bleeding were limited in the pivotal program. The product also had drug-interaction and renal-dosing constraints.
The FDA label included restrictions for severe renal impairment and concomitant use with strong P-glycoprotein inhibitors. Patients with significant renal dysfunction had increased exposure, which complicated routine use [1].
What is the market size for betrixaban?
The current branded market is effectively zero because Bevyxxa is no longer an active commercial product.
At launch, the addressable U.S. population appeared substantial because millions of patients are hospitalized annually with acute medical illnesses. The commercially reachable population was much smaller. Only a subset had elevated VTE risk, acceptable bleeding risk and a clinical rationale for extended prophylaxis after discharge.
A practical market-sizing framework is:
| Market layer |
Betrixaban opportunity |
| All annual U.S. hospital admissions |
Large theoretical population |
| Acutely ill medical admissions |
Smaller target group |
| Patients at elevated VTE risk |
Restricted population |
| Patients suitable for extended prophylaxis |
Narrower population |
| Patients selected by hospital protocols |
Limited adoption pool |
| Current commercial demand |
Negligible |
Published sales did not approach the scale required for a sustainable standalone anticoagulant franchise. The product's discontinuation indicates that actual demand, pricing power and commercial return were materially below the level needed to support continued promotion.
What is the future market projection for betrixaban?
The base-case projection is no meaningful commercial recovery through 2030.
Base case
Betrixaban remains commercially inactive. No major company reintroduces it, and generic manufacturers do not invest in a limited market with a discontinued brand and uncertain demand.
Upside case
A relaunch would require a sponsor to obtain commercial rights, rebuild manufacturing and distribution, and demonstrate renewed demand for extended prophylaxis. A new clinical strategy could also be required to support a broader indication. This scenario has low probability because competing anticoagulants already have extensive outcomes data and established reimbursement.
Downside case
The product remains unavailable, with residual activity limited to academic publications, historical clinical-trial analysis and possible patent or regulatory-record research.
| Projection period |
Expected commercial position |
| 2024-2025 |
No material branded sales; no visible development momentum |
| 2026-2027 |
Continued commercial inactivity |
| 2028-2030 |
Low probability of relaunch; generic entry unlikely to create material value |
| Beyond 2030 |
Commercial relevance dependent on new clinical evidence or strategic acquisition |
Are there betrixaban generic or biosimilar risks?
Betrixaban is a small-molecule drug, so the relevant pathway is an abbreviated new drug application, not a biosimilar application.
The main generic risks are:
- Abbreviated approval based on bioequivalence
- Potential use of the FDA's discontinued-drug framework
- Low development incentive because the brand is no longer commercially active
- Limited hospital demand
- Possible need to establish a stable supply chain and commercial distribution network
The absence of a large active branded market reduces the value of a Paragraph IV challenge. A generic entrant could obtain regulatory approval yet still generate little revenue.
What patents protected betrixaban?
Betrixaban was developed under Portola's intellectual-property portfolio. Protection historically included composition-of-matter, pharmaceutical-composition, formulation and manufacturing claims. The relevant patent term depended on individual filing dates, patent-term adjustment and any patent-term extension.
The commercial patent analysis is now less important than the product's market withdrawal. Even if residual patent rights remained during portions of the original commercial period, they did not create a durable market franchise after discontinuation.
Does betrixaban have Orange Book protection?
FDA Orange Book status should be evaluated by product-specific listing and current patent-record status. The principal commercial issue is that patent exclusivity cannot restore demand after a product has been withdrawn from active promotion.
Betrixaban also had no biologic exclusivity, no biosimilar interchangeability issue and no reference-product exclusivity structure comparable to a biologic medicine.
Was betrixaban involved in patent litigation or settlements?
Betrixaban did not develop the high-profile generic litigation record associated with blockbuster anticoagulants such as Eliquis or Xarelto. The absence of a large active commercial franchise limited the incentive for extensive Paragraph IV litigation and settlement negotiations.
There is no commercially significant generic settlement structure driving current betrixaban launch timing. Any evaluation of historical patents should distinguish:
- Patent validity and enforceability
- Regulatory exclusivity
- Product availability
- Actual commercial demand
- Manufacturing economics
These factors do not currently align in favor of a large betrixaban generic opportunity.
What manufacturing and IP barriers affect betrixaban?
Betrixaban's manufacturing requirements are less restrictive than those of a biologic, but commercial supply would still require validated active-pharmaceutical-ingredient production, finished-dose manufacturing, quality controls and regulatory documentation.
Key barriers include:
- Re-establishing qualified API suppliers
- Demonstrating consistent impurity control
- Validating dissolution and bioequivalence performance
- Managing food-effect requirements
- Supporting renal-dose variants
- Maintaining pharmacovigilance and labeling infrastructure
- Establishing demand sufficient to justify manufacturing scale
The most important barrier is commercial rather than technical. A manufacturer can potentially produce a small-molecule factor Xa inhibitor, but the expected return from a narrow, discontinued market is weak.
How strong is the betrixaban competitive position?
Betrixaban's current competitive position is weak.
| Category |
Assessment |
| Clinical differentiation |
Limited |
| FDA label breadth |
Narrow |
| Physician familiarity |
Low relative to apixaban and rivaroxaban |
| Hospital adoption |
Limited |
| Patent-based value |
Low as a current commercial driver |
| Manufacturing complexity |
Manageable |
| Generic opportunity |
Technically possible but commercially unattractive |
| Relaunch probability |
Low |
| Revenue growth potential |
Minimal without new clinical evidence |
The drug's principal scientific value is historical: it demonstrated that extended oral anticoagulation could reduce thromboembolic events in selected acutely ill patients. Its commercial value is substantially lower because the indication did not generate durable adoption.
Key Takeaways
- Betrixaban was FDA-approved in 2017 as Bevyxxa for extended VTE prophylaxis in selected acutely ill medical patients.
- The pivotal APEX trial supported approval in a high-risk subgroup but did not produce a broad all-patient efficacy result under its hierarchical design.
- The drug was not approved for atrial fibrillation, acute VTE treatment or recurrent-VTE prevention.
- Bevyxxa is commercially discontinued, and current revenue is effectively zero.
- Apixaban and rivaroxaban have stronger labels, larger clinical databases and much greater commercial scale.
- Betrixaban has no meaningful biosimilar risk because it is a small molecule.
- Generic approval is technically possible, but market demand and return on investment are weak.
- A commercial relaunch before 2030 is unlikely without new clinical evidence, a broader indication or a major strategic transaction.
FAQs
Is betrixaban still available by prescription?
Betrixaban is not an active mainstream commercial anticoagulant in the U.S. Bevyxxa was discontinued after limited market adoption.
Is betrixaban stronger than Eliquis?
No clinical evidence establishes betrixaban as superior to Eliquis, or apixaban, across major anticoagulation indications. Eliquis has a substantially broader approved label and larger clinical and commercial position.
Can betrixaban be used for atrial fibrillation?
No. Betrixaban was not FDA-approved for stroke prevention in nonvalvular atrial fibrillation.
Will a generic version of betrixaban launch?
A generic launch is possible in principle, but the limited market, product discontinuation and competition from established anticoagulants make a commercially meaningful launch unlikely.
What happened to the company that developed betrixaban?
Portola Pharmaceuticals developed and commercialized betrixaban. Alexion acquired Portola in 2020, and Alexion was later acquired by AstraZeneca. Betrixaban did not become a significant ongoing product within the acquiring companies' portfolios.
References
-
U.S. Food and Drug Administration. (2017). Bevyxxa (betrixaban) prescribing information. FDA.
-
Cohen, A. T., Harrington, R. A., Goldhaber, S. Z., Hull, R. D., Wiens, B. L., Gold, A., Hernandez, A. F., & APEX Investigators. (2016). Extended thromboprophylaxis with betrixaban in acutely ill medical patients. New England Journal of Medicine, 375(6), 534-544.
-
U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA.
-
Portola Pharmaceuticals, Inc. (2017). Bevyxxa approved by FDA for extended-duration prophylaxis of venous thromboembolism in acutely ill medical patients. Company announcement.
-
Alexion Pharmaceuticals, Inc. (2020). Alexion completes acquisition of Portola Pharmaceuticals. Company announcement.
